## Slide Template for Reporting to Facility Administration **User Guide**

These template slides have been prepared as an example of an antimicrobial stewardship program (ASP) can use antimicrobial use (AU) data in routine reports to senior hospital leadership. Reporting to leadership at least annually is recommended and included in the REPORTING element of the CDC Core Elements of Hospital Antibiotic Stewardship Programs. These template slides should be considered a minimum set of information to provide to hospital leadership and should be supplemented, where appropriate, with information on facility-specific interventions and outcomes.

Slide 1- Title Slide- Please update with the name of the facility and the name(s) of the stewardship leader(s) for the facility. Some ASP programs have an internal acronym or logo. It is always best to use this for your slide presentation template where possible.

Slide 2- Definition of Antimicrobial Stewardship- This slide is a quote taken from the CDC Core Elements Document. It is always important to re-introduce stewardship to the leadership group. If there are facility-specific program objectives, missions and/or goals statements, these should be substituted here.

## Slide 3- Comparative SAAR Values for Hospitals within a GROUP using the Group functionality within NHSN

Please note, for this example, we have blinded the names of other facilities in our Group within NHSN. Blinding of the facility identity should be discussed with group members before any facility-specific data are shared.

To create graphs comparing SAAR data from your facility to others within an NHSN group, you will use the Targeted Assessment for Stewardship (TAS) Reports in the Antimicrobial Uses and Resistance Module tab in the Analysis section of NHSN (Figure 1).

There are three Group level reports included here. These are discussed in more detail in the NHSN Quick Reference Guide: TAS Report- Group-level. For this example, we use the report for Adult SAAR Types- Group and Facility, but as you can see similar reports are available for pediatric and neonatal SAAR data.

ated (DA) Module Procedure-Associated (PA) Module HAI Antimicrobial Resistance (DA+PA Modul robial Use and Resistance Module microbial Use Data nent for Stewardship (TAS) Reports Targeted Assess TAS TAS Report - Adult SAAR Types - Group and Facility
TAS TAS Report - Adult SAAR Types - Location Groups (Sepa
TAS TAS Report - Adult SAAR Types - Locations
TAS TAS Report - Pediatric SAAR Types - Group and Facility TAS TAS Report - Pediatric SAAR Types - Location Groups (Se TAS TAS Report - Pediatric SAAR Types - Locations TAS TAS Report - Neonatal SAAR Types - Cocations
TAS TAS Report - Neonatal SAAR Types - Group ar
TAS TAS Report - Neonatal SAAR Types - Location
Antimicrobial Use Data - 2014 Baseline SAARs d Eacility Antimicrobial Resistance Data Data Quality MDRO/CDI Module - LABID Event Reporting MDRO/CDI Module - Infection Surveillance MDRO/CDI Module - Process Measures MDRO/CDI Module - Outcome Measures COVID-19 Module CMS Reports Baseline Set 1 Baseline Set 2 Av Custom Reports

🗼 Analysis Reports

To create graphs, we will manipulate Excel output from the standard NHSN report. Therefore, the only modification you need to the existing report is to change the format to XLS.

Figure 1: NHSN Analysis Options



(Figure 2) From there you select Run and the Excel file should appear in your downloads folder on your computer.

Show descriptive va	ariable names <u>(Prir</u>	nt List)		Analysis Data Set: AU_TAS	Type: TAS	Last Generated:	June 27, 2023 12:15 F		
Title/Format	Time Period	Filters	Display Options						
Fitle:									
TAS Report - Adu	It SAAR Types -	Group and F	acility						
Format:									
°∰	° Pdf	۲		rtf					

Figure 2: TAS Report Modification for Excel Export

To prepare a graph from the NHSN Excel Output, you scroll to the data section of interest in the Excel output. In this case, it is the second area of output in the file. (The first area gives the SAAR category rankings for the total of all hospitals in the group, the second area gives the SAAR data for each facility in the group for the ALL SAAR category).

To quickly create a graph, you highlight the columns you would like to include, in this case it is the facility name (or the code we have assigned in this blinded example) and the SAAR (Figure 3). You can select non-adjacent rows by holding down the control key when making your selection. Then you go to insert and select the chart type you desire from your dropdown

	ile Home	Insert Page Layout Formulas Data Review	View	Help Acr	obat 🛛 🖓 Tell me what you war	x to do											
[] Phe	atTable Recomm PivotT	Pictures Online Shapes I cons Pictures I literations	ds <sup>-</sup> ⊞Ge ot - ⊅M	t Add-ins 7 Add-ins =	isio Data 🛃 People Graph Rec Asuelizer	P mended harts	2-D Column	5	D Line Column Win/ Loss	Sicer Timeline Unix	Text Header Box & Footer	WordArt Sign	ature Object	π ⊆ Equation Sym	2 fool		
M	55 <b>v</b>	1 2					3-D Column							.,			
							3-0 (0000	lee lee									
1	A	C	D	Ł	F	G	110 48	- 48 - 60			1	ĸ	L	M	N	0	P
41	TAS Report	t - Adult SAAR Tuner - Group and Facility					2-D Bar										
43	ind nepos	r Huan show rypes - croup and racinty					tal. Inst	in the second se									
44	Facilities v	vithin the Group Ranked by AU-CAD					EE										
45							3-D Bar										
46	Group Ide	ntified SAAR Target: All antibacterials = (	0)				(3)a /100	/2000									
47								<u> </u>									
48	As of: Sep	tember 25					Isl More Column (	harts -									
49																	
50	Date Rang	e: AU_TAS summaryYH 2021H2 to 2022H	11														
51	16.111	ALL BRADIN THAN															
52	in (((popul	ation = ADULT ())															
54	Encility Paul	Eacility Nama	State	Modical	ScNumber of Redr	SAARTur	a Facility ALL-CA	D // Three hist	art use drugs within SAAR	Tune (Percentage)	Antimicro	Prodicted	Dave Proc	SAAD	95% Confiden	Internal	
50	1		NC	M	1048	ALL	01	103 VANC(16)	PIPERWT(16): CEEEP(10):	(Abe (rescentage)	9103	9455 97	15083	0.963	0.943.0.983	entervar	
56	2	B	NC	M	538	ALL	55	79 PIPERWT	13): CEFEP(12): VANC(12):		5579	6403.45	10896	0.871	0.849.0.894		
57	3	c	GA	M	286	ALL	47	96 CEFTRX(1	3); PIPERWT(17); VANC(16)	6	4796	4123.17	6353	1.163	1.131, 1.196		
58	17	CDA-TEST FACILITY DUKE	NC	G	149	ALL	3	62 CEFTX(17)	; VANC(15); PIPERWT(11);		5293	5206.91	8456	1.017	0.989, 1.044		
59	4	D	GA	м	678	ALL	42	261 CEFEP(15)	; VANC(15); METRO(13);		4261	3838.53	6214	1.11	1.077, 1.144		
60	5	E	GA	M	382	ALL	41	29 CEFTRX(2)	2); VANC(13); CEFEP(12);		4129	4281.17	6947	0.964	0.935, 0.994		
61	6	F	GA	м	579	ALL	41	122 PIPERWT(	24); VANC(15); CEFTRX(11)	6	4122	4561.58	7457	0.904	0.876, 0.932		
62	7	G	GA	U	256	ALL	37	22 PIPERWT(	19); CEFTRX(17); VANC(15)	6	3722	4119.99	6479	0.903	0.875, 0.933		
63	8	н	GA	U	158	ALL	34	92 CEFTRX(1	3); PIPERWT(18); VANC(14)	6	3492	3393.98	5236	1.029	0.995, 1.063		
64	9	1	VA	M	328	ALL	34	155 PIPERWT(	23); VANC(23); CEFTRX(10)	6	3455	3328.58	5054	1.038	1.004, 1.073		
65	10	1	SC	G	210	ALL	29	29 VANC(19)	CEFTRX(13); PIPERWT(11)	6	2929	2603.95	4004	1.125	1.085, 1.166		
00	11	ĸ	NC	<i>c</i>	150	ALL	20	98 CEFEP(13)	; PIPERWI (13); CEFTRX(12	5	2798	2583.85	4228	1.083	1.043, 1.124		
60	12	L	CA	0	249	ALL	23	DO CEETRY/1	21); VANC(12); CEFTRA(11)	6	2317	1969.27	4063	1.105	1.116, 1.213		
60	10	N	NC	M	150	ALL	2	DIDEPINAL	16)- VANC(13), FIFERWT(13)	<i>h</i>	2300	2090 22	4002	0.054	0.727 0.900		
70	15	0	GA	M	200	ALL	21	58 PIPERWT(	29): CEETRX(19): VANC(16)	le le	2258	2432 13	3895	0.928	0.891 0.967		
71	16	p	NC	6	218	ALL	2	30 CEETRX(1)	PIPERWT(14): CEFEP(10)	):	2230	2414	4013	0.924	0.886.0.963		
72	18	R	GA	U	198	ALL	20	20 PIPERWT(	21); CEFTRX(21); VANC(12)	6	2020	2461.02	3783	0.821	0.786, 0.857		
73	19	s	GA	G	119	ALL	19	39 CEFTRX(1	); PIPERWT(18); AZITH(9);		1939	2414.89	3667	0.803	0.768, 0.839		
74	20	т	GA	U	97	ALL	13	11 VANC(15)	CEFTRX(15); PIPERWT(14)	lc .	1711	1725.13	2594	0.992	0.946, 1.040		
75	21	U	NC		167	ALL	15	36 PIPERWT(	18); CEFTRX(18); VANC(16)	lc .	1536	1542.73	2554	0.996	0.947, 1.046		
76	22	v	NC	U	190	ALL	15	504 VANC(19)	CEFTRX(13); PIPERWT(12)	6	1504	1251.15	1855	1.202	1.143, 1.264		
77	1	W	NC	U	76	ALL	15	604 PIPERWT(	22); VANC(19); CEFTRX(13]	6	1504	1542.2	2468	0.975	0.927, 1.025		
70																	

Figure 3: Creating a Graph from NHSN Excel Output

The graph you get as a result will not be sorted by SAAR value. Sorting by the SAAR value for all of the facilities allows for quick visual interpretation of where your facility ranks compared to the others in

your group. The graph can easily be sorted this way. In this case, you select all of the data in this section of the Excel File (See shaded area in Figure 4). Then select Sort & Filter from the Excel top banner. In the pop up indicate to sort by the SAAR value.

6. If the ol and data should be validated for accura	cy.						
Source of aggregate data: 2017 NHSN SAAR Data							
Data contained in this report were last generated o	n June						
			Chart Title		Sort		? ×
National Healthcare Safety Network	1.4				*Al Add Level X Delete Level PA Conv Leve	el 🔺 👻 Ontions 🖂 Ma	r data bas beaders
	1.2	1.1.1.1	1.1		Column Cost Co	area area area area area area area area	
TAS Report - Adult SAAR Types - Group and Facility	1 -		un Hiller u		Sort by SAAR Cell Values	Smallest to Large	est 🔍
Facilities within the Group Ranked by AU-CAD	0.8						
Group Identified SAAR Target: All antibacterials = (	0 0.2						
	0						
As of: September 25			BEOF 2200				
		FAC				OK	Cancel
Date Range: AU_TAS summaryYH 2021H2 to 2	2022H1	TEST					
		DA-					
if (((population = ""ADULT"" ) ))		0					
FacilityRai Facility Name	State	Medical Sci	Number of Beds SAARType Fa	cility AU-CAD (I Three high	est use drugs within SAAR Type (Percentage	) Antimicrol Predicted Da	ys Pres SAAR 95% ConfidenceInterva
1 A	NC	M	1048 ALL	9103 VANC(16);	PIPERWT(16); CEFEP(10);	9103 9455.97	15083 0.963 0.943, 0.983
2 B	NC	M	538 ALL	5579 PIPERWT(	13); CEFEP(12); VANC(12);	5579 6403.45	10896 0.871 0.849, 0.894
3 C	GA	M	286 ALL	4796 CEFTRX(18	); PIPERWT(17); VANC(16);	4796 4123.17	6353 1.163 1.131, 1.196
17 CDA-TEST FACILITY DUKE	NC	G	149 ALL	362 CEFTX(17)	; VANC(15);PIPERWT(11);	5293 5206.91	8456 1.017 0.989, 1.044
4 D	GA	M	678 ALL	4261 CEFEP(15)	; VANC(15); METRO(13);	4261 3838.53	6214 1.11 1.077, 1.144
5 E	GA	M	382 ALL	4129 CEFTRX(22	!); VANC(13); CEFEP(12);	4129 4281.17	6947 0.964 0.935, 0.994
6 F	GA	M	579 ALL	4122 PIPERWT(	24); VANC(15); CEFTRX(11);	4122 4561.58	7457 0.904 0.876, 0.932
7 G	GA	U	256 ALL	3722 PIPERWT(	19); CEFTRX(17); VANC(15);	3722 4119.99	6479 0.903 0.875, 0.933
8 H	GA	U	158 ALL	3492 CEFTRX(18	I); PIPERWT(18); VANC(14);	3492 3393.98	5236 1.029 0.995, 1.063
9 1	VA	M	328 ALL	3455 PIPERWT(	23); VANC(23); CEFTRX(10);	3455 3328.58	5054 1.038 1.004, 1.073
10 J	SC	G	210 ALL	2929 VANC(19);	CEFTRX(13); PIPERWT(11);	2929 2603.95	4004 1.125 1.085, 1.166
11 K	NC		150 ALL	2798 CEFEP(13)	; PIPERWT(13); CEFTRX(12);	2798 2583.85	4228 1.083 1.043, 1.124
12 L	NC	G	249 ALL	2317 PIPERWT(	21); VANC(12); CEFTRX(11);	2317 1989.27	3065 1.165 1.118, 1.213
13 M	GA	U	138 ALL	2300 CEFTRX(17	'); VANC(15); PIPERWT(13);	2300 2572.33	4062 0.894 0.858, 0.931
14 N	NC	M	252 ALL	2295 PIPERWT(	16); VANC(13); CEFTRX(13);	2295 2989.23	4635 0.768 0.737, 0.800
15 O	GA	M	299 ALL	2258 PIPERWT(	29); CEFTRX(19); VANC(16);	2258 2432.13	3895 0.928 0.891, 0.967
16 P	NC	G	218 ALL	2230 CEFTRX(19	); PIPERWT(14); CEFEP(10);	2230 2414	4013 0.924 0.886, 0.963
18 R	GA	U	198 ALL	2020 PIPERWT(	21); CEFTRX(21); VANC(12);	2020 2461.02	3783 0.821 0.786, 0.857
19 S	GA	G	119 ALL	1939 CEFTRX(19	); PIPERWT(18); AZITH(9);	1939 2414.89	3667 0.803 0.768, 0.839
20 T	GA	U	97 ALL	1711 VANC(15);	CEFTRX(15); PIPERWT(14);	1711 1725.13	2594 0.992 0.946, 1.040
21 U	NC		167 ALL	1536 PIPERWT(	18); CEFTRX(18); VANC(16);	1536 1542.73	2554 0.996 0.947, 1.046
22 V	NC	U	190 ALL	1504 VANC(19);	CEFTRX(13); PIPERWT(12);	1504 1251.15	1855 1.202 1.143, 1.264
w	NC	U	76 ALL	1504 PIPERWT(	22); VANC(19); CEFTRX(13);	1504 1542.2	2468 0.975 0.927, 1.025

Figure 4: Unsorted Graph Output

## When you do, the graph will convert to this (Figure 5):



Figure 5: Sorted Graph

From here, you can manipulate the graph using traditional Excel functionality.

An external benchmark is also useful in these sorts of data displays. This can be accessed using data from CDC Antibiotic Resistance & Patient Safety Portal, Antibiotic Use and Stewardship Module.

*For State Specific Data:* In the Antibiotic Resistance & Patient Safety Portal, you can select the option for Inpatient Antibiotic use and scroll down to the graphic entitled: SAAR Data by State Map. You can hover over your state (in our example case we use North Carolina) to see the 50<sup>th</sup> percentile SAAR. In this case, all antibacterial agents for adult units is selected. (Figure 6: Antibiotic Resistance & Patient Safety Portal screen shot showing how to identify state-specific benchmark).



Figure 6:Antibiotic Resistance & Patient Safety Portal screen shot showing how to identify state-specific benchmark

In our final graphic (Figure 7), we have added a benchmark line for the 50<sup>th</sup> percentile SAAR for North Carolina for reference.



Figure 7: Final Figure

Similar steps can be followed for specific SAAR types by using the rest of the data downloaded with the Adult SAAR Types- Group and Facility report used for the All Antimicrobials graphic. If you continue to scroll you will have data for the broad spectrum antibacterial agents predominantly used for hospital-onset infections (Figure 8).



Figure 8: Broad Spectrum Antibacterial Agents for Hospital-Onset Infections

Using data from the Antibiotic Resistance & Patient Safety Portal (Figure 9) set for the BSHO SAAR category and adult population, you find your new benchmark for this graph (Figure 10).



Figure 9: Antibiotic Resistance & Patient Safety Portal screen shot showing how to identify state-specific benchmark set to BSHO Adult Units



Figure 10: Broad Spectrum Antibacterial Agents for Hospital-Onset Infections with Benchmark

## **References:**

CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.

CDC. 2021 National Healthcare Safety Network Antimicrobial Use Option Report. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2022. Available at: https://www.cdc.gov/nhsn/pdfs/datastat/2021-AU-Report-508.pdf

This work was funded by Centers for Disease Control & Prevention Safety and Healthcare Epidemiology Prevention Research Development (SHEPheRD) Program- Contract 2022 Domain 1-A001.